400 Technology Square, 10th Floor
About IFM TherapeuticsIFM Therapeutics is a privately held biopharmaceutical company based in Cambridge, Massachusetts. Seeded by Atlas Venture, the company was founded in 2015 by an international group of preeminent scientists and physicians to discover and develop small molecules that modulate novel targets in the innate immune system as next generation therapies for cancer, autoimmunity, and inflammatory disorders. Drugs in the IFM portfolio are expected to significantly improve upon standard of care agents in terms of efficacy and safety. For more information, please visit www.ifmthera.com.
CEO: Gary D. Glick
Chief Development Officer: Dennis Dean
Chief Scientific Officer: Shomir Ghosh
28 articles with IFM Therapeutics
As the largest center for biotech startups in the U.S., the Boston/Cambridge, Massachusetts area often acts as a marker for the entire industry. Here’s a look at the Massachusetts M&A deals so far.
IFM Therapeutics announced the completion of the previously-announced acquisition of its subsidiary, IFM Tre, by Novartis.
4/18/2019In the first quarter of 2019, more than 30 life science companies* announced expansions, new locations, increased funding, new trial and product launches and various other news pointing to a growing industry.
Novartis to Acquire IFM Tre to Develop First-In-Class NLRP3 Antagonist Portfolio Targeting Innate Immune System
Acquisition of IFM Therapeutics subsidiary gives Novartis full rights to one clinical and two pre-clinical NLRP3 antagonist programs
Novartis will pay $310 million upfront for the Boston-based inflammation company IFM Tre. IFM TRE is very much an early-stage company, with one compound, IFM-2427, in an early Phase I clinical trial, and two preclinical assets.
IFM Therapeutics Announces Dosing of First Subjects in Phase 1 Healthy Volunteer Study of Lead NLRP3 Antagonist, IFM-2427
Announcement marks first human trial for an NLRP3 antagonist
The drugs target a protein called STING (stimulator of interferon genes), which plays an important role in the innate immune system, which is the body’s first line of defense against various pathogens.
IFM Therapeutics, LLC Launches New Subsidiary, IFM Due, to Advance cGAS/STING Antagonists for Serious Inflammatory and Autoimmune Diseases
World-renowned researcher, Andrea Ablasser, M.D., appointed IFM Due Founding Scientist and named to IFM's Scientific Advisory Board
IFM Therapeutics is launching its second subsidiary in less than a year. This morning, the Boston-based company, launched IFM Due (pronounced du-way), a subsidiary company developing a suite of cGAS inhibitors and STING antagonists that can target diseases like NASH, lupus and Parkinson’s.
IFM Therapeutics (IFM), a privately held biopharmaceutical company focused on developing therapies that modulate novel targets in the innate immune system, today announced the discovery of new immune system triggers that are associated with certain inflammatory diseases.
Clarivate Analytics list honors Dr. Luigi Franchi and Dr. Eicke Latz as most highly cited scientists, ranking in the top one percent globally
Seasoned industry leader to provide expert counsel to help guide strategic growth of IFM Therapeutics, LLC
Twentyeight-Seven Therapeutics (28-7), announced it had completed a $65 million Series A financing. It was co-led by founding investor MPM Capital and Novartis Venture Fund. Joining them were Johnson & Johnson Innovation – JJDC, Vertex Ventures, Longwood Fund, and Astellas Venture Management.
Findings support continued development of small-molecule NLRP3 antagonists for treatment of inflammatory diseases
IFM Therapeutics Announces New Publication in Nature Reviews Drug Discovery Examining NLRP3 as a Target in Serious Inflammatory and Immune-Mediated Diseases
Comprehensive review surveys the potential therapeutic role of NLRP3 inhibition across a range of common diseases with unmet medical need
IFM Therapeutics, LLC Launches Subsidiary, IFM Tre, with $31 Million Series A Financing to Develop NLRP3 Antagonists for Inflammatory Diseases
Subsidiary responsible for clinical development of NLRP3 antagonist portfolio with lead candidate expected in the clinic in 2019
Deal of the Year Highlights Bristol-Myers Squibb's Acquisition of IFM's Preclinical STING and NLRP3 Agonist Programs
IFM Therapeutics' New Research Demonstrates Direct Link between Inflammasome Activation and Amyloid-β Pathology in Alzheimer's Disease
The team publishing the pre-clinical research includes IFM co-founder Eicke Latz, M.D., Ph.D., University of Bonn, and newly appointed IFM clinical advisory board member, Michael Heneka, M.D., Director of the Department of Neurodegenerative Diseases and Gerontopsychiatry, University Hospital of Bonn, Germany.
Heneka, who serves as Director of the Department of Neurodegenerative Diseases and Gerontopsychiatry at the University Hospital of Bonn, Germany, will join a group of seven distinguished immunotherapy pioneers on the IFM Therapeutics clinical advisory board.